Shopping Cart
- Remove All
- Your shopping cart is currently empty
Ridinilazole (SMT19969) is a novel narrow-spectrum nonabsorbable antibiotic. Ridinilazole showed potent inhibition of C. difficile (MIC90=0.125 mg/L) and was markedly more active than either metronidazole (MIC90 = 8 mg/L) or vancomycin (MIC90 = 2 mg/L).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $46 | In Stock | |
5 mg | $98 | In Stock | |
10 mg | $163 | In Stock | |
25 mg | $297 | In Stock | |
50 mg | $397 | In Stock | |
100 mg | $572 | In Stock | |
200 mg | $777 | In Stock | |
1 mL x 10 mM (in DMSO) | $98 | In Stock |
Description | Ridinilazole (SMT19969) is a novel narrow-spectrum nonabsorbable antibiotic. Ridinilazole showed potent inhibition of C. difficile (MIC90=0.125 mg/L) and was markedly more active than either metronidazole (MIC90 = 8 mg/L) or vancomycin (MIC90 = 2 mg/L). |
Targets&IC50 | C. difficile:8 µg/mL (MIC90) |
In vivo | ridinilazole , a novel antibacterial currently under development for the treatment of CDI.?Owing to its highly targeted spectrum of activity and ability to spare the normal gut microbiota, ridinilazole provides significant advantages over metronidazole and vancomycin, the mainstay antibiotics for CDI.?Ridinilazole is bactericidal against C. difficile and exhibits a prolonged post-antibiotic effect.?Furthermore, treatment with ridinilazole results in decreased toxin production. |
Alias | SMT19969 |
Molecular Weight | 388.42 |
Formula | C24H16N6 |
Cas No. | 308362-25-6 |
Smiles | c1cc(ccn1)-c1nc2ccc(cc2[nH]1)-c1ccc2nc([nH]c2c1)-c1ccncc1 |
Relative Density. | 1.372 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 55 mg/mL (141.6 mM) | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.